Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Kadmon

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Cancer Gene Therapy|July 14, 2007
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancerH Wang, G Yang, T L Timme, et al.
Cancer Surveys|January 1, 1991
Experimental oncogene induced prostate cancerT C Thompson, D Kadmon, T L Timme, et al.
Endocrinology|March 1, 1994
Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesisT L Timme, L D Truong, V W Merz, et al.
Cancer|February 1, 1993
Transgenic models for the study of prostate cancerT C Thompson, L D Truong, T L Timme, et al.
Oncogene|March 2, 1995
Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancerT C Thompson, S H Park, T L Timme, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1992
Transforming growth factor beta 1 as a biomarker for prostate cancerT C Thompson, L D Truong, T L Timme, et al.
Molecular Endocrinology (Baltimore, Md.)|April 1, 1991
Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progressionV W Merz, G J Miller, T Krebs, et al.
Prostate Cancer and Prostatic Diseases|February 23, 2005
The emerging role of the PI3-K-Akt pathway in prostate cancer progressionL Li, M M Ittmann, G Ayala, et al.
Expert Opinion on Biological Therapy|December 1, 2001
In situ gene therapy for prostate cancer: immunomodulatory approachesT C Thompson, T L Timme, S Ebara, et al.
The Journal of Urology|May 24, 2001
Bilateral nerve graft during radical retropubic prostatectomy: 1-year followupE D Kim, R Nath, D Kadmon, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Cancer Gene Therapy|July 14, 2007
IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancerH Wang, G Yang, T L Timme, et al.
Cancer Surveys|January 1, 1991
Experimental oncogene induced prostate cancerT C Thompson, D Kadmon, T L Timme, et al.
Endocrinology|March 1, 1994
Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesisT L Timme, L D Truong, V W Merz, et al.
Cancer|February 1, 1993
Transgenic models for the study of prostate cancerT C Thompson, L D Truong, T L Timme, et al.
Oncogene|March 2, 1995
Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancerT C Thompson, S H Park, T L Timme, et al.
Journal of Cellular Biochemistry. Supplement|January 1, 1992
Transforming growth factor beta 1 as a biomarker for prostate cancerT C Thompson, L D Truong, T L Timme, et al.
Molecular Endocrinology (Baltimore, Md.)|April 1, 1991
Elevated transforming growth factor-beta 1 and beta 3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progressionV W Merz, G J Miller, T Krebs, et al.
Prostate Cancer and Prostatic Diseases|February 23, 2005
The emerging role of the PI3-K-Akt pathway in prostate cancer progressionL Li, M M Ittmann, G Ayala, et al.
Expert Opinion on Biological Therapy|December 1, 2001
In situ gene therapy for prostate cancer: immunomodulatory approachesT C Thompson, T L Timme, S Ebara, et al.
The Journal of Urology|May 24, 2001
Bilateral nerve graft during radical retropubic prostatectomy: 1-year followupE D Kim, R Nath, D Kadmon, et al.
Pageof 7